See more : Novozymes A/S (NZYM-B.CO) Income Statement Analysis – Financial Results
Complete financial analysis of DNA Chip Research Inc. (2397.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DNA Chip Research Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Independence Gold Corp. (IEGCF) Income Statement Analysis – Financial Results
- Strategic Oil & Gas Ltd. (SOGFF) Income Statement Analysis – Financial Results
- Bet Shemesh Engines Holdings (1997) Ltd (BSEN.TA) Income Statement Analysis – Financial Results
- Zenith Exports Limited (ZENITHEXPO.BO) Income Statement Analysis – Financial Results
- Alrov Properties and Lodgings Ltd. (ALRPR.TA) Income Statement Analysis – Financial Results
DNA Chip Research Inc. (2397.T)
About DNA Chip Research Inc.
DNA Chip Research Inc. develops DNA microarrays in Japan. The company offers research and development, contract research, and diagnostic support services. It offers Tbone EX Kit for Japanese forensic laboratories in police force and universities. The company also develops EGFR (epidermal growth factor receptor) Liquid gene analysis software, a disease diagnosis program for detecting mutations in the gene encoding EGFR using DNA extracted from plasma samples or cancer tissues and determining drug efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer, as well as focuses on developing a gene panel for testing cancers using sequencing technology. The company was incorporated in 1999 and is based in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 490.46M | 327.54M | 427.94M | 324.50M | 361.00M |
| Cost of Revenue | 424.11M | 363.11M | 338.72M | 258.32M | 272.00M |
| Gross Profit | 66.35M | -35.58M | 89.22M | 66.18M | 89.00M |
| Gross Profit Ratio | 13.53% | -10.86% | 20.85% | 20.40% | 24.65% |
| Research & Development | 69.43M | 65.00M | 64.00M | 65.00M | 51.00M |
| General & Administrative | 28.00M | 33.00M | 33.00M | 31.00M | 28.00M |
| Selling & Marketing | 227.00M | 229.00M | 158.00M | 142.00M | 134.00M |
| SG&A | 255.00M | 262.00M | 191.00M | 173.00M | 162.00M |
| Other Expenses | 0.00 | -406.00K | 28.89M | 2.07M | 0.00 |
| Operating Expenses | 324.57M | 327.31M | 255.83M | 238.38M | 217.00M |
| Cost & Expenses | 748.68M | 690.43M | 594.55M | 496.70M | 489.00M |
| Interest Income | 2.00K | 3.00K | 5.00K | 5.00K | 0.00 |
| Interest Expense | 1.51M | 1.68M | 0.00 | 2.66M | 0.00 |
| Depreciation & Amortization | 41.86M | 17.82M | 16.47M | 21.62M | 18.00M |
| EBITDA | -217.00M | -345.07M | -151.00M | -150.57M | -106.00M |
| EBITDA Ratio | -44.24% | -106.70% | -36.41% | -46.81% | -29.36% |
| Operating Income | -258.22M | -362.89M | -166.61M | -172.20M | -124.00M |
| Operating Income Ratio | -52.65% | -110.79% | -38.93% | -53.06% | -34.35% |
| Total Other Income/Expenses | 11.82M | 1.89M | 33.52M | 673.00K | -4.48M |
| Income Before Tax | -246.39M | -361.00M | -133.10M | -171.52M | -128.00M |
| Income Before Tax Ratio | -50.24% | -110.22% | -31.10% | -52.86% | -35.46% |
| Income Tax Expense | 1.90M | 1.35M | 950.00K | 950.00K | 290.00K |
| Net Income | -248.29M | -362.34M | -134.05M | -172.47M | -128.00M |
| Net Income Ratio | -50.62% | -110.63% | -31.32% | -53.15% | -35.46% |
| EPS | -39.07 | -61.76 | -23.15 | -30.38 | -25.15 |
| EPS Diluted | -39.07 | -61.76 | -23.15 | -30.38 | -25.15 |
| Weighted Avg Shares Out | 6.36M | 5.87M | 5.79M | 5.68M | 5.09M |
| Weighted Avg Shares Out (Dil) | 6.36M | 5.87M | 5.79M | 5.68M | 5.09M |
Source: https://incomestatements.info
Category: Stock Reports